$1,570.23 general Payment -- Boehringer Ingelheim to Dr. Christopher Clark
This page provides a detailed analysis of a $1,570.23 general payment from Boehringer Ingelheim to Dr. Christopher Clark. Data is from the CMS Open Payments (Sunshine Act) database.
Payment Details
| Field | Value |
|---|---|
| Amount | $1,570.23 |
| Payment Type | general |
| Payment Nature | Education |
| Pharmaceutical Company | Boehringer Ingelheim |
| Physician | Dr. Christopher Clark |
| NPI Number | 1462774197 |
| Physician Specialty | Rheumatology |
| Location | Boston, MA |
| Date of Payment | 2025-11-14 |
| Related Drug/Device | Opdivo |
Understanding general Payments
general payments are one of several categories of financial transfers from pharmaceutical and medical device companies to physicians that must be reported under the Sunshine Act. Understanding the type and context of a payment is important for evaluating its significance. Not all payments are equal -- a research grant has very different implications than a promotional speaking fee.
Related Reports
Data from CMS Open Payments (Sunshine Act). Payment does not imply wrongdoing. AI analysis is not medical or legal advice. Consult your healthcare provider about any concerns.